Peddock Capital Advisors LLC Purchases 245,728 Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA)

Peddock Capital Advisors LLC raised its stake in Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) by 546.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 290,720 shares of the company's stock after acquiring an additional 245,728 shares during the quarter. Peddock Capital Advisors LLC owned approximately 0.59% of Akoya Biosciences worth $1,419,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in AKYA. Polar Capital Holdings Plc increased its stake in shares of Akoya Biosciences by 4.2% in the third quarter. Polar Capital Holdings Plc now owns 1,579,756 shares of the company's stock valued at $7,346,000 after buying an additional 64,286 shares during the period. Kent Lake Capital LLC bought a new position in shares of Akoya Biosciences during the third quarter valued at $3,471,000. Bank of New York Mellon Corp raised its stake in shares of Akoya Biosciences by 8.3% during the third quarter. Bank of New York Mellon Corp now owns 132,834 shares of the company's stock valued at $618,000 after acquiring an additional 10,233 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Akoya Biosciences by 5.9% during the third quarter. Schonfeld Strategic Advisors LLC now owns 129,500 shares of the company's stock worth $602,000 after purchasing an additional 7,200 shares during the period. Finally, Nisa Investment Advisors LLC grew its stake in shares of Akoya Biosciences by 10,169.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,059 shares of the company's stock worth $30,000 after purchasing an additional 6,000 shares during the last quarter. 79.42% of the stock is currently owned by institutional investors and hedge funds.

Akoya Biosciences Stock Up 0.7 %

Shares of NASDAQ AKYA traded up $0.03 during trading on Wednesday, hitting $4.11. 80,801 shares of the company traded hands, compared to its average volume of 184,003. The firm has a market capitalization of $202.95 million, a price-to-earnings ratio of -2.78 and a beta of 1.52. The business's fifty day moving average is $4.52 and its 200 day moving average is $4.65. The company has a debt-to-equity ratio of 1.41, a quick ratio of 2.94 and a current ratio of 3.45. Akoya Biosciences, Inc. has a fifty-two week low of $3.04 and a fifty-two week high of $8.80.

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) last issued its earnings results on Monday, March 4th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.05. Akoya Biosciences had a negative return on equity of 110.24% and a negative net margin of 65.53%. The business had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.12 million. During the same period in the previous year, the company posted ($0.50) EPS. Equities research analysts predict that Akoya Biosciences, Inc. will post -0.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AKYA. JPMorgan Chase & Co. reduced their price objective on shares of Akoya Biosciences from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 6th. Canaccord Genuity Group reiterated a "buy" rating and set a $10.00 price target on shares of Akoya Biosciences in a report on Tuesday, March 5th. Finally, UBS Group boosted their price objective on Akoya Biosciences from $7.00 to $7.50 and gave the company a "buy" rating in a research note on Tuesday, March 5th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Akoya Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $9.07.

Insider Buying and Selling

In other Akoya Biosciences news, CEO Brian Mckelligon sold 7,500 shares of the company's stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $4.94, for a total transaction of $37,050.00. Following the transaction, the chief executive officer now owns 224,368 shares in the company, valued at $1,108,377.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 7.30% of the stock is owned by company insiders.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.